Dolutegravir for second-line antiretroviral therapy: the beat goes on
- PMID: 38142693
- DOI: 10.1016/S2214-109X(23)00569-7
Dolutegravir for second-line antiretroviral therapy: the beat goes on
Conflict of interest statement
We declare no competing interests.
Comment on
-
Clinical outcomes with second-line dolutegravir in people with virological failure on first-line non-nucleoside reverse transcriptase inhibitor-based regimens in South Africa: a retrospective cohort study.Lancet Glob Health. 2024 Feb;12(2):e282-e291. doi: 10.1016/S2214-109X(23)00516-8. Epub 2023 Dec 21. Lancet Glob Health. 2024. PMID: 38142692 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
